UCL has been shortlisted for the Times Higher Education Entrepreneurial University of the Year Award.
The Award, which is sponsored by the National Centre for Entrepreneurship Education, seeks to recognise an institution which has developed an unparalleled environment for fostering enterprise throughout its staff and students and delivered significant impact in its local community, across the UK and overseas.
UCLB patented technology used to develop a potential new treatment for Corneal Surface Disease
14 February 2012
Researchers at UCL have made a significant advance towards developing a treatment for Corneal Surface Disease, using RAFTTM; a UCLB patented technology licensed to Tap Biosystems.
The development was led by Professor Robert Brown at UCL's Tissue Repair and Engineering Centre (TREC) and Professor Julie Daniels at the UCL's Institute of Ophthalmology, in collaboration with TAP Biosystems and funding from the Technology Strategy Board.
Professor Daniels used an innovative method of synthetic tissue production, known as RAFTTM, which uses collagen to create corneal tissue; closely mimicking that of actual human cornea. It has the potential to significantly improve the success rates of cornea repair surgery and will allow people with corneal surface disease to have replacements without waiting for eye donors.
The patented RAFTTM technology has previously been used to create a wide range of different artificial human tissues. This is the first time it has successfully been used to mimic that of human cornea tissue.
"This project has advanced our understanding of what is required to engineer a tissue in the laboratory for patient transplantation," explains Julie Daniels, Professor of Regenerative Medicine and Cellular Therapy at the Institute of Ophthalmology. "It's exciting because it provides a real prospect for treating patients with blinding corneal surface disease, using a stem cell populated tissue equivalent that is simply, quickly and reproducibly prepared."
Dr Rachel Hemsley, Senior Business Manager at UCLB said "This project is an exciting contribution of disciplines bringing together regenerative medicine and tissue engineering with the aim of meeting a key medical need of restoring sight to patients. This advance has arisen through the long standing relationship between IoO at UCL, UCLB and Tap Biosystems".
Image:stem cell colonies that have been stained with a dye to make them visible.
UCLB is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK's top research-led universities.
UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from the laboratory to market.
UCLB supports UCL's Grand Challenges of increasing UCL's positive impact on and contribution to Global Health, Sustainable Cities, Intercultural Interaction and Human Wellbeing.
For further information, please visit www.uclb.com
About Tap Biosytems
TAP Biosystems (formerly The Automation Partnership) provides advanced automation systems and services to improve productivity in life science research, development and production.
For further information, please visit www.tapbiosystems.com